We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.2%
2 Industrials 0.08%
3 Consumer Staples 0.05%
4 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
276
DELISTED
Soleno Therapeutics
SLNO
$155K 0.01%
8,164
– –
ARNA
277
DELISTED
Arena Pharmaceuticals Inc
ARNA
$153K 0.01%
+2,200
New +$169K
CYRX icon
278
CryoPort
CYRX
$761M
$151K 0.01%
2,900
-20,000
-87% -$1.22M
SLDB icon
279
Solid Biosciences
SLDB
$794M
$131K ﹤0.01%
1,574
-50,960
-97% -$5.64M
BXRX
280
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$129K ﹤0.01%
71
– –
KNTE
281
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$62K ﹤0.01%
2,000
– –
RCKT icon
282
Rocket Pharmaceuticals
RCKT
$340M
$61K ﹤0.01%
1,400
– –
RETA
283
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$60K ﹤0.01%
+600
New +$70K
HZNP
284
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$56K ﹤0.01%
+603
New +$50.9K
LEGN icon
285
PUT
Legend Biotech
LEGN
$3.59B
$44K ﹤0.01%
+1,500
New +$40.9K
CGEM icon
286
Cullinan Oncology
CGEM
$1.01B
$42K ﹤0.01%
+1,000
New +$40.6K
IGMS
287
DELISTED
IGM Biosciences
IGMS
$23K ﹤0.01%
300
– –
SRPT icon
288
Sarepta Therapeutics
SRPT
$1.57B
$10K ﹤0.01%
+134
New +$12.4K
KPTI icon
289
Karyopharm Therapeutics
KPTI
$43.5M
$9K ﹤0.01%
53
– –
BLUE
290
DELISTED
bluebird bio
BLUE
$8K ﹤0.01%
22
– –
CGEN icon
291
PUT
Compugen
CGEN
$222M
$4K ﹤0.01%
500
– –
ACRS icon
292
CALL
Aclaris Therapeutics
ACRS
$726M
– –
-235,800
Closed -$1.53M
ADVM
293
CALL
DELISTED
Adverum Biotechnologies
ADVM
– –
-25,870
Closed -$2.8M
ADVM
294
PUT
DELISTED
Adverum Biotechnologies
ADVM
– –
-4,480
Closed -$486K
ALNY icon
295
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-50,000
Closed -$6.5M
APLT
296
DELISTED
Applied Therapeutics
APLT
– –
-33,002
Closed -$726K
APLT
297
PUT
DELISTED
Applied Therapeutics
APLT
– –
-200,000
Closed -$4.4M
ARCT icon
298
PUT
Arcturus Therapeutics
ARCT
$164M
– –
-100,000
Closed -$4.34M
ARVN icon
299
CALL
Arvinas
ARVN
$518M
– –
-232,700
Closed -$19.8M
ARVN icon
300
PUT
Arvinas
ARVN
$518M
– –
-100,000
Closed -$8.49M
10 11
12
13 14

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.